Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, First-in-Human Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-Human Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Ad26-ZIKV-001 (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 06 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 17 Jul 2018 Planned End Date changed from 15 Aug 2019 to 31 Oct 2019.
    • 22 May 2018 Planned End Date changed from 27 Jun 2019 to 15 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top